news

Zyesami shows promise in critical COVID-19 patients with respiratory failure

Preliminary data indicate that Zyesami reduces the length of hospital stay in critical COVID-19 patients treated with High Flow Nasal Cannula (HFNC) therapy or mechanical ventilation.

old man in a hospital bed on a ventilator surrounded by monitors and doctors wearing PPE

In a Phase IIb/III trial, critically ill COVID-19 patients with respiratory failure treated with Zyesami™ (aviptadil, previously RLF-100) plus maximal standard of care (SOC) were discharged sooner than those who received SOC and placebo. If authorised for use, Zyesami would be the first drug indicated specifically for COVID-19 patients who are critically ill with respiratory failure.

Dr Jonathan Javitt, Chief Executive Officer of NeuroRx, commented: “We are greatly encouraged by these preliminary findings and believe they are indicative of a biologic effect of aviptadil in hastening recovery from critical COVID-19.  We expect to discuss with the US Food and Drug Administration (FDA) and other regulatory authorities the submission of an Emergency Use Authorization (EUA) so that ZYESAMI can be available for treating this population that is at immediate risk of death and for which there is no approved therapy.”

A total of 203 patients participated in the study; 136 were given Zyesami, while 67 received the SOC. A total of 138 patients (91 Zyesami, 47 SOC) survived through Day 28. Ninety-six patients (65 Zyesami, 31 SOC) were discharged from the hospital by Day 28. Data analysis is ongoing. The primary endpoint of the trial was the resolution of respiratory failure within 28 days after treatment started. The secondary endpoints were patient survival, time to intensive care unit discharge, time to hospital discharge, time to return to NIAID score of 6-8 and safety. 

The preliminary data includes 28 days of follow up, since patient survival has improved since the start of the pandemic, no differences in patient survival have been observed so far. Patients are now being followed through day 60 to assess this further. The study has also not identified an overall difference in recovery from respiratory failure. However, investigators are now working to confirm the timing of each case of recovery from medical records, once completed the study’s investigators’ committee will review each case prior to patient-level unblinding of this endpoint. Those data are expected within a few weeks. A blinded sub-study of radiographic improvement is also underway.

Zyesami did meet some of its secondary efficacy endpoints – in patients treated with High Flow Nasal Cannula (HFNC) therapy and mechanical ventilation, it showed an advantage of at least 40 percent in 15 of 16 comparisons. This difference includes at least a five-day median reduction in hospital stay. The largest difference observed was among those treated with HFNC who experienced a median of 11 fewer days in hospital (15 versus 26 for placebo plus SOC).

Dr Javitt added: “To our knowledge this is the first demonstration of clinically and statistically-significant benefit by any therapeutic agent in patients with COVID-19 respiratory failure in a randomised, double blind, prospective trial.  Other COVID-19 therapeutics have demonstrated clinical advantage in patients with non-critical COVID-19 (ordinal scale 4 and 5) but have not demonstrated benefit in those with Critical COVID-19 (ordinal scale 6 and 7). Steroids have demonstrated benefit in open label studies.  However, no randomised controlled trial to date has shown efficacy when patients are in respiratory failure and require High Flow Nasal Cannula, non-invasive ventilation or mechanical ventilation to maintain blood oxygenation. Zyesami, if authorised, would be the first drug for such critically ill patients.  Of note, the patients who received either drug or placebo in this trial also received all approved and standard of care treatments including remdesivir, anti-cytokine drugs, steroids and anticoagulants.” 

No unexpected side effects have been identified. The most common side effects of Zyesami were mild to moderate diarrhea (seen in 30 percent of Zyesami-treated patients versus 1.5 percent of placebo-treated patients) and systemic hypotension (low blood pressure) seen in 31 Zyesami-treated patients versus 25 placebo patients. There were two deaths in the study related to hypotension, both of which occurred more than a week after treatment. One patient was in the Zyesami group, and the other was in the placebo group. All potentially serious adverse effects were investigated by a board-certified critical care physician together with site investigators and none was deemed drug-related.

Related organisations

Related people

Related diseases & conditions

,

2 responses to “Zyesami shows promise in critical COVID-19 patients with respiratory failure”

  1. Steve H says:

    Thomas, not a hard choice at all. Take a look at the final data.

    “NeuroRx Announces ZYESAMI™ (aviptadil, RLF-100) Met the Primary Endpoint of Its Phase 2b/3 Clinical Trial and Also Demonstrated a Meaningful Benefit in Survival from Critical COVID-19
    RADNOR, Pa., March 29, 2021 /PRNewswire/ — NeuroRx, Inc. today reports 60-day results of the Phase 2b/3 trial of intravenously-administered ZYESAMI™ (aviptadil acetate) for the treatment of respiratory failure in critically-ill patients with COVID-19, which is being developed in collaboration with Relief Therapeutics Holding AG (SIX:RLF, OTCQB:RLFTF). Across all patients and sites, ZYESAMI™ met the primary endpoint for successful recovery from respiratory failure at days 28 (P = .014) and 60 (P = .013) and also demonstrated a meaningful benefit in survival (P = < .001) after controlling for ventilation status and treatment site."

    "In addition to the robust overall significance across all 196 treated patients at all 10 clinical sites, the prespecified analysis of recovery from respiratory failure is clinically and statistically significant in the 127 patients treated by High Flow Nasal Cannula (HFNC) (P = .02), compared to those treated with mechanical or non-invasive ventilation at tertiary care hospitals. In this group, ZYESAMI™ patients had a 71% chance of successful recovery by day 28 vs. 48% in the placebo group (P = .017) and a 75% rate of successful recovery by day 60 vs. 55% in the placebo group (P = .036). Eighty-four percent (84%) of HFNC patients treated at tertiary medical centers with ZYESAMI™ survived to day 60 compared with 60% of those treated with placebo (P = .007)."

    "To the company's knowledge, ZYESAMI™ is the first COVID-19 therapeutic to demonstrate advantages in both survival and recovery from critical COVID-19 in a randomized, double-blind multicenter trial. On the basis of these findings, NeuroRx plans to apply immediately to the United States Food and Drug Administration ("FDA") for Emergency Use Authorization (EUA) and to subsequently submit a New Drug Application (NDA)."

  2. So, Zyesami survival is 91/136= 67%
    And placebo survival is 47/67= 70%

    Hard choice?

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Send this to a friend